CHEMOTHERAPY OF GASTRIC CANCER: RANDOMIZED CLINICAL STUDY (PHASE III) FE VS FEP
Main researcher
: ROTH, ANTON (41573) Assistants
POPIJAČ-KLJUČAR, STANKA (91784)
KOLARIĆ, KRSTO (21661)
ŽUPANC, DARKO (119423)
NOLA-SPEVEC, IVANA (900440)
Type of research: developmental Duration from: 04/01/91. to 12/31/94. Papers on project (total): 8
Institution name: Središnji institut za tumore i slične bolesti, Zagreb (74) Department/Institute: Department for Medical Oncology Address: Ilica 197 City: 10000 - Zagreb, Croatia
Communication
Phone: 385 (0) 01 17-21-11
Fax: 385 (0) 01 17-55-36
Summary: The most frequently used cytostatics in treatment of
advanced gastric cancer are: 5-fluo-rouracil,doxorubicin,
4-epi-doxorubicin, mitomycin C, methotrexat, nitrosoureas and more
recently cis DDP and etoposid. It has been proved that combination of the
cytostatitcs as compared to the single agent obtains higher percentage of
the remissions, but has no impact on the patients survival. By randomized
clinical study FE vs. FEP (phase III) in patients with advanced gastric
cancer will be examined the effect of high doses of 5-fluorouracil ( 1000
mg/m2 in 6 hour infusion) through five days and high doses of
4-epi-doxorubicin ( 120 mg/m2) on the first day of treatment and be
compared with antitumors effect of the same combination plus cis DDP ( 30
mg/m2 on days 2. and 4. of treatment ). In this way the study will answer
a question whether there is the difference between two used protocols in
the number of objective remissions of the disease, complete remissions,
survivals and toxic side effects. Patients will be randomized in two
groups ( A and B). The group A will be treated with 5-fluorouracil and
4-epi-doxorubucin, while the group B with 5-fluorouracil,
4-epi-doxorubicin and cis DDP.The cycles will be repeated every 4 weeks.
The usual criteria for evaluation of treatment results (WHO/UICC) will be
used. In all patients before treatment the following examinations will be
done: blood tests,ECG, X-ray of lungs and stomach, gastroscopy, ultrasoud
of abdomen, histological verification of the disease, and in the case of
need computerized tomography. The examinations which will prove the
presence of the disease will be repeated through every 2-3 cycles of the
treatment, in order to see the effect of the treatment. Eighty to one
hundred patients will be included in the study.
Research goals: In the randomozed clinical study (phase III) will be
studied the antitumorous efect of high doses of 5-Fluorouracil (1000mg/m2
in6-hour infusion) during five days and high doses of epirubicin
(120mg/m2) on day l. in correlation with the same combination
ofcytostatics + cis-DDP (30mg/m2 on days 2. and 4.).This study willanswer
if the addition of cis-DDP to 5-Fluororacil and epirubicin in creases the
antitumor activity in patients with metastatic gastric cancer. This
investigation will show if there will be the difference between the two
randomized groups of patients in: 1. The number of objectivs remissions of
diesease 2. The number of complete remission of disease 3. Survival of
patients 4. Toxic side effects of the treatment It could be expected the at
a number of objectivs remissions willbe higher in the group of patients
treated with the combination of three cytostatics (5-Fluorouracil,
epirubicin and cis-DDP), butit is uncertain if the number of complete
remissions and patients surviving will be higher. Toxic side effects of
the treatment will be probably higher inthe group of patients with three
cytostatics. Until now,the treatment results of patients with the
metastatic gastric cancer by use of high doses of 5-Fluorouracil and
epirubicin in combination with cis-DDP are not published. Other information about the project.